var data={"title":"Oxaliplatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Oxaliplatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6692?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">see &quot;Oxaliplatin: Drug information&quot;</a> and <a href=\"topic.htm?path=oxaliplatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Oxaliplatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709183\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hypersensitivity/Anaphylactic reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anaphylactic reactions to oxaliplatin have been reported and may occur within minutes of administration. Epinephrine, corticosteroids, and antihistamines have been employed to alleviate symptoms of anaphylaxis.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204261\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Eloxatin [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6821523\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Eloxatin;</li>\n      <li>Oxaliplatin Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028793\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Alkylating Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028825\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">see &quot;Oxaliplatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual protocols; details concerning dosing in combination regimens should also be consulted. In obese patients, there are no pediatric specific recommendations; in obese adult patients, the actual body weight (full weight) is used for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Solid tumors; refractory or relapsed:</b> Limited data available; several regimens reported; efficacy results highly variable; has shown limited activity in pediatric patients (primarily some delayed tumor progression reported) and an acceptable safety profile; should not be used first-line; reserved for refractory cases; patients should be hydrated prior to and during administration (eg, 3 L/m<sup>2</sup>/day) (Hartman 2011; Lam 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lam 2015; MacGregor 2009:</i> Children and Adolescents: IV: 130 mg/m<sup>2</sup> over 2 hours on day 1 in combination with etoposide with/without ifosfamide every 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Georger 2011; Macy 2013: </i>Children and Adolescents: IV: 100 mg/m<sup>2</sup> over 2 hours on day 1 of a 14-day cycle in combination with gemcitabine or fluorouracil/leucovorin</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Hartmann 2011:</i> Children and Adolescents: IV: 85 mg/m<sup>2</sup> over 2 hours on day 1 in combination with irinotecan (day 1) and gemcitabine (day 1 and 8)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuroblastoma; refractory or relapsed: </b>Limited data available; efficacy results highly variable; should not be used first-line; reserved for refractory case. Children &ge;2 years and Adolescents: IV: 105 mg/m<sup>2</sup> on day 1 in combination with doxorubicin on a 21-day cycle; a higher dose of 130 mg/m<sup>2</sup> was more effective but associated with higher incidence of hematologic toxicity (Mascarenhas 2013; Tran 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colorectal cancer; advanced</b>: IV: 85 mg/m<sup>2</sup> every 2 weeks until disease progression or unacceptable toxicity; administer in combination with fluorouracil/leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Colon cancer; stage III (adjuvant):</b> IV: 85 mg/m<sup>2</sup> every 2 weeks for 12 cycles; administer in combination with fluorouracil/leucovorin calcium</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustments for toxicity:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute toxicities:</b> Longer infusion time (6 hours) may mitigate acute toxicities (eg, pharyngolaryngeal dysesthesia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neurosensory events:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persistent (&gt;7 days) grade 2 neurosensory events:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adjuvant treatment of stage III colon cancer: Reduce dose to 75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Advanced colorectal cancer: Reduce dose to 65 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Consider withholding oxaliplatin for grade 2 neuropathy lasting &gt;7 days despite dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Persistent (&gt;7 days) grade 3 neurosensory events: Consider discontinuing oxaliplatin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastrointestinal toxicity (grade 3/4) occurring despite prophylactic treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjuvant treatment of stage III colon cancer: Delay next dose until recovery from toxicity, then reduce dose to 75 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Advanced colorectal cancer: Delay next dose until recovery from toxicity, then reduce dose to 65 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hematologic toxicity (grade 4 neutropenia, febrile neutropenia, or grade 3/4 thrombocytopenia):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adjuvant treatment of stage III colon cancer: Delay next dose until neutrophils recover to &ge;1,500/mm<sup>3</sup> and platelets recover to &ge;75,000/mm<sup>3</sup>, then reduce dose to 75 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Advanced colorectal cancer: Delay next dose until neutrophils recover to &ge;1,500/mm<sup>3</sup> and platelets recover to &ge;75,000/mm<sup>3</sup>, then reduce dose to 65 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pulmonary toxicity (unexplained respiratory symptoms, including nonproductive cough, dyspnea, crackles, pulmonary infiltrates):</b> Discontinue until interstitial lung disease or pulmonary fibrosis have been excluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rhabdomyolysis:</b> Discontinue for signs/symptoms of rhabdomyolysis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sepsis or septic shock:</b> Withhold treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &ge;30 mL/minute: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Reduce dose from 85 mg/m<sup>2</sup> to 65 mg/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: CrCl &ge;20 mL/minute: In a study with a limited number of patients with mild to moderate impairment, defined by the authors as CrCl 20 to 59 mL/minute (determined using 24-hour urine collection), oxaliplatin was well tolerated, suggesting a dose reduction may not be necessary in patients with CrCl &ge;20 mL/minute receiving every-3-week dosing (dose range: 80 to 130 mg/m<sup>2</sup> every 3 weeks) (Takimoto 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: There are no dosage adjustments provided in the manufacturer's labeling; however, some have suggested that dosage adjustment is not necessary (Doroshow 2003; Synold 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204242\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Eloxatin: 50 mg/10 mL (10 mL [DSC]); 100 mg/20 mL (20 mL [DSC])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg/10 mL (10 mL); 100 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204229\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028831\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oxaliplatin is associated with moderate emetic potential and preventative antiemetics recommended (Basch 2011; Dupuis 2011; Roila 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer as IV infusion over 2 to 6 hours. Flush infusion line with D5W prior to and following administration of oxaliplatin. Do <b>not</b> use IV administration sets containing aluminum. When used in combination with a fluoropyrimidine (eg, 5-FU), infuse oxaliplatin first.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation; monitor IV site for redness, swelling, or pain. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Information conflicts regarding use of warm or cold compresses. Cold compresses could potentially precipitate or exacerbate peripheral neuropathy (de Lemos 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132766\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204256\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); do not freeze. Protect concentrated solution from light (store in original outer carton). According to the manufacturer, solutions diluted in D5W for infusion are stable up to 6 hours at room temperature of 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F) or up to 24 hours under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Oxaliplatin solution diluted with D5W to a final concentration of 0.7 mg/mL (polyolefin container) has been shown to retain &gt;90% of the original concentration for up to 30 days when stored at room temperature or refrigerated; artificial light did not affect the concentration (Andre 2007). As this study did not examine sterility, refrigeration would be preferred to limit microbial growth. Solutions diluted for infusion do not require protection from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028794\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of stage III colon cancer (adjuvant) and advanced colorectal carcinoma (FDA approved in adults); has also been used in the treatment of relapsed/refractory childhood solid tumors including CNS and non-CNS tumors </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204295\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Oxaliplatin may be confused with Aloxi, carboplatin, cisplatin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204291\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Chest pain, edema, flushing, peripheral edema, thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Dizziness, fatigue, headache, insomnia, pain, peripheral neuropathy (may be dose limiting), rigors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Alopecia, palmar-plantar erythrodysesthesia, skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Dehydration, hypokalemia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dyspepsia, dysphagia (acute), flatulence, gastroesophageal reflux disease, hiccups, mucositis, nausea, stomatitis, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Dysuria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia, leukopenia, neutropenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST, increased serum bilirubin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (includes urticaria, pruritus, facial flushing, shortness of breath, bronchospasm, diaphoresis, hypotension, syncope)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (redness, swelling, pain) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ocular: Abnormal lacrimation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Renal: Increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Cough, dyspnea, epistaxis, pharyngitis, pharyngolaryngeal dysesthesia, rhinitis, upper respiratory tract infection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening (reported with mono- and combination therapy): Acute renal failure, anaphylactic shock, anaphylactoid reaction, aphonia, ataxia, blepharoptosis, cerebral hemorrhage, colitis, cranial nerve palsy, decreased deep tendon reflex, deafness, decreased visual acuity, diplopia, eosinophilic pneumonitis, fasciculations, febrile neutropenia, hematuria, hemolysis, hemolytic anemia (immuno-allergic), hemolytic-uremic syndrome, hemorrhage, hepatic failure, hepatic fibrosis (perisinusoidal), hepatic sinusoidal obstruction syndrome (SOS; veno-occlusive disease), hepatitis, hepatotoxicity, hypertension, hypomagnesemia, hypoxia, idiopathic noncirrhotic portal hypertension (nodular regenerative hyperplasia), increased INR, increased serum alkaline phosphatase, infusion related reaction (extravasation [including necrosis]), interstitial nephritis (acute), interstitial pulmonary disease, intestinal obstruction,  Lhermittes' sign, metabolic acidosis, myoclonus, neutropenic enterocolitis, neutropenic infection (sepsis), optic neuritis, pancreatitis, prolonged prothrombin time, pulmonary fibrosis, prolonged Q-T interval on ECG, purpura, rectal hemorrhage, renal tubular necrosis, reversible posterior leukoencephalopathy syndrome (RPLS), rhabdomyolysis, seizure, sepsis, septic shock, temporary vision loss, thrombocytopenia (immuno-allergic), torsades de pointes, trigeminal neuralgia, ventricular arrhythmia, visual field loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204247\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to oxaliplatin, other platinum-containing compounds, or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Pregnancy, breast-feeding; severe renal impairment (CrCl &lt;30 mL/minute)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204232\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Grade 3 and 4 neutropenia occurs commonly with oxaliplatin in combination with fluorouracil and leucovorin; sepsis, neutropenic sepsis, and septic shock have been reported with oxaliplatin (some fatal). Delay oxaliplatin treatment until neutrophils are &ge;1500/mm<sup>3</sup>; withhold treatment for sepsis or septic shock. Reduce the dose after recovery from grade 4 neutropenia or neutropenic fever.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiotoxicity: QT prolongation and ventricular arrhythmias, including fatal torsades de pointes have been reported in postmarketing surveillance. ECG monitoring is recommend in patients with heart failure, bradyarrhythmias, concomitant medications known to cause QT prolongation (including class Ia and III antiarrhythmics), and electrolyte abnormalities. Avoid use in patients with congenital long QT syndrome. Monitor potassium and magnesium prior to and periodically during treatment; correct hypokalemia and hypomagnesemia prior to treatment initiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: Oxaliplatin is an irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI toxicity: Oxaliplatin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Fluorouracil and leucovorin are associated with GI adverse events; the incidence of GI toxicity is increased when oxaliplatin is administered with fluorouracil and leucovorin. Mucositis, stomatitis, GI bleeding, and GI obstruction have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity/anaphylactoid reactions: <b>[US Boxed Warning]: Anaphylactic reactions have been reported with oxaliplatin (may occur within minutes of administration); symptoms may be managed with epinephrine, corticosteroids, antihistamines, </b> and discontinuation; oxygen and bronchodilators have also been used (Kim 2009). Grade 3 or 4 hypersensitivity has been observed. Allergic reactions are similar to reactions reported with other platinum analogs and may occur with any cycle. Reactions typically occur after multiple cycles; in retrospective reviews, reaction occurred at a median of 7 to 9 cycles, with an onset of 5 to 70 minutes (Kim 2009; Polyzos 2009). Symptoms may include bronchospasm (rare), erythema, hypotension (rare), pruritus, rash, and/or urticaria; previously-untreated patients have also experienced flushing, diaphoresis, diarrhea, shortness of breath, chest pain, hypotension, syncope, and disorientation. According to the manufacturer, rechallenge is contraindicated (deaths due to anaphylaxis have been associated with platinum derivatives). In patients rechallenged after mild hypersensitivity, reaction recurred at a higher level of severity; for patients with severe hypersensitivity, rechallenge (with 2 to 3 days of antihistamine and corticosteroid premedication, and prolongation of infusion time) allowed for 2 to 4 additional oxaliplatin cycles; however, rechallenge was not feasible in nearly two-thirds of patients due to the severity of the initial reaction (Polyzos 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Hepatotoxicity (including rare cases of hepatitis and hepatic failure) has been reported. Liver biopsy has revealed peliosis, idiopathic noncirrhotic portal hypertension (including nodular regenerative hyperplasia), sinusoidal alterations, perisinusoidal fibrosis, and veno-occlusive lesions. The presence of hepatic vascular disorders (including veno-occlusive disease) should be considered, especially in individuals developing portal hypertension or who present with increased liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuropathy: Two different types of peripheral sensory neuropathy may occur: The first type of neuropathy is an acute presentation (within hours to 1 to 2 days), reversible (resolves within 14 days), with primarily peripheral symptoms that are often exacerbated by cold (may include pharyngolaryngeal dysesthesia); avoid mucositis prophylaxis with ice chips, exposure to cold temperatures, or consumption of cold food/beverages during or within hours after oxaliplatin infusion (may exacerbate symptoms); this acute neuropathy commonly recurs with subsequent doses. Cold-triggered neuropathy may last up to 7 days after oxaliplatin administration (Grothey 2011). The second type of neuropathy is a more persistent (&gt;14 days) presentation that often interferes with daily activities (eg, writing, buttoning, swallowing); these symptoms may improve in some patients upon discontinuing treatment. In a retrospective evaluation of patients treated with oxaliplatin for colorectal cancer, the incidence of peripheral sensory neuropathy was similar between diabetic and nondiabetic patients (Ramanathan 2010). Several retrospective studies (as well as a small, underpowered randomized trial) have suggested calcium and magnesium infusions before and after oxaliplatin administration may reduce incidence of cumulative sensory neuropathy; however, a recent abstract of an ongoing randomized, placebo-controlled, double-blind study in patients with colorectal cancer suggests there is no benefit of calcium and magnesium in preventing sensory neuropathy or in decreasing oxaliplatin discontinuation rates (Loprinzi 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: May cause pulmonary fibrosis (may be fatal); withhold treatment for unexplained pulmonary symptoms (eg, crackles, dyspnea, nonproductive cough, pulmonary infiltrates) until interstitial lung disease or pulmonary fibrosis are excluded.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Reversible posterior leukoencephalopathy syndrome: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) have been reported. Signs/symptoms include headache, mental status changes, seizure, blurred vision, blindness and/or other vision changes; may be associated with hypertension. Diagnosis is confirmed with brain imaging.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rhabdomyolysis: Rhabdomyolysis (including fatal cases) has been reported with oxaliplatin. Discontinue if signs/symptoms of rhabdomyolysis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; increased toxicity may occur. Reduce initial dose in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Elderly patients are more sensitive to adverse events, particularly diarrhea, dehydration, hypokalemia, leukopenia, fatigue, and syncope.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Other warnings/precautions:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Oxaliplatin is for IV administration. Administration via the intraperitoneal route (not an approved administration route) is associated with peritoneal hemorrhage and hemorrhagic complications (Charrier 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299798\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OCT2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204236\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13031&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May increase the serum concentration of OCT2 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Platinum Derivatives may decrease the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: Platinum Derivatives may enhance the myelosuppressive effect of Taxane Derivatives. Administer Taxane derivative before Platinum derivative when given as sequential infusions to limit toxicity. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: Platinum Derivatives may enhance the adverse/toxic effect of Topotecan. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204238\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204249\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies at one-tenth the equivalent human dose. Women of childbearing potential should be advised to avoid pregnancy and use effective contraception during treatment. Males and females of reproductive potential desiring children should consider fertility preservation prior to therapy (Levi 2015; O'Neil 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1028833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, blood chemistries, including serum creatinine, ALT, AST, and bilirubin (prior  to each cycle); electrolytes, including potassium and magnesium (prior to and periodically during treatment); INR and prothrombin time (in patients on oral anticoagulant therapy); signs of neuropathy, hypersensitivity reaction, respiratory effects, and/or RPLS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204231\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Oxaliplatin, a platinum derivative, is an alkylating agent. Following intracellular hydrolysis, the platinum compound binds to DNA forming cross-links which inhibit DNA replication and transcription, resulting in cell death. Cytotoxicity is cell-cycle nonspecific.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F204246\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 440 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90% primarily albumin and gamma globulin (irreversible binding to platinum) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nonenzymatic (rapid and extensive), forms active and inactive derivatives</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Oxaliplatin ultrafilterable platinum (terminal): Median: 293 hours; range: 187 to 662 hours (Beaty 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Oxaliplatin ultrafilterable platinum: Distribution: Alpha phase: 0.4 hours; Beta phase: 16.8 hours; Terminal: 391 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~54%); feces (~2%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323568\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Oxaliplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/10 mL (10 mL): $60.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/20 mL (20 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Oxaliplatin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $240.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539908\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ai Heng (CN);</li>\n      <li>Crisapla (UY);</li>\n      <li>Dacotin (IN);</li>\n      <li>Dacplat (AR);</li>\n      <li>Eloxatin (AE, AT, BE, BG, BH, BR, CH, CL, CN, CO, CR, CY, CZ, DE, DK, DO, EE, ES, FI, GB, GT, HK, HN, HR, ID, IE, IL, IT, JO, KR, KW, LU, MT, MX, MY, NI, NL, NZ, PA, PE, PH, PL, PT, QA, RO, SA, SE, SG, SI, SV, TH, TR, TW, VN);</li>\n      <li>Eloxatine (FR, LB, RU, VE);</li>\n      <li>Elplat (JP);</li>\n      <li>Entia (TH);</li>\n      <li>Henplatin (PH);</li>\n      <li>Kebir (PY);</li>\n      <li>Liplatin (KR);</li>\n      <li>Loxatron (LK);</li>\n      <li>Lyoxatin (VN);</li>\n      <li>Meslatin (PH);</li>\n      <li>Olatin (TW);</li>\n      <li>Olipcis (MX);</li>\n      <li>Oplat (CO);</li>\n      <li>Oxalatin (AU);</li>\n      <li>Oxalee (PH);</li>\n      <li>Oxalem (PH);</li>\n      <li>Oxalip (TH, TW);</li>\n      <li>Oxalitin (KR);</li>\n      <li>Oxalotin (BD);</li>\n      <li>Oxaltic (AR);</li>\n      <li>Oxaltie (EC, LB, LK, PK);</li>\n      <li>Oxapla (KR);</li>\n      <li>Oxaplat (TH);</li>\n      <li>Oxaplin (MY);</li>\n      <li>Oxerin (CO);</li>\n      <li>Oxitan (TH, ZW);</li>\n      <li>Oxitel (PH);</li>\n      <li>Oxol (LK, TH, ZW);</li>\n      <li>Planitox (VN);</li>\n      <li>Platinox (PH);</li>\n      <li>Pleoxtin (KR);</li>\n      <li>Plusplatin (EC);</li>\n      <li>Ranxor (SG);</li>\n      <li>Rexta (ID);</li>\n      <li>Rezykol (UA);</li>\n      <li>Riptam (MX);</li>\n      <li>Sanroxa (ID);</li>\n      <li>Sindoxplatin (PH);</li>\n      <li>Sinoxal (HR);</li>\n      <li>Vizoksal (UA);</li>\n      <li>X-Plat (LK);</li>\n      <li>Xaliplat (PY);</li>\n      <li>Xaloplat (BD);</li>\n      <li>Zildox (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Andr&eacute; P, Cisternino S, Roy AL, et al, &quot;Stability of Oxaliplatin in Infusion Bags Containing 5% Dextrose Injection,&quot; <i>Am J Health Syst Pharm</i>, 2007, 64(18):1950-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/17823107/pubmed\" target=\"_blank\" id=\"17823107\">17823107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al; American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2011;29(31):4189-4198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/21947834 /pubmed\" target=\"_blank\" id=\"21947834 \">21947834 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beaty O, Berg S, Blaney S, et.al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a children&rsquo;s oncology group study. <i>Pediatr Blood Cancer</i>. 2010;55:440-445.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/20658614/pubmed\" target=\"_blank\" id=\"20658614\">20658614</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Lemos ML, Walisser S, Management of extravasation of oxaliplatin. <i>J Oncol Pharm Pract</i>. 2005;11(4):159-162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/16595069/pubmed\" target=\"_blank\" id=\"16595069\">16595069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doroshow JH, Synold TW, Gandara D, et al, &quot;Pharmacology of Oxaliplatin in Solid Tumor Patients With Hepatic Dysfunction: A Preliminary Report of the National Cancer Institute Organ Dysfunction Working Group,&quot; <i>Semin Oncol</i>, 2003, 30(4 Suppl 15):14-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/14523790 /pubmed\" target=\"_blank\" id=\"14523790 \">14523790 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, &ldquo;Guideline for the Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients,&rdquo; <i>Pediatr Blood Cancer</i>, 2011, 57(2):191-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Geoerger B, Chisholm J, Deley ML, et al. Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: an innovative therapy for children with Cancer European Consortioum Study. <i>European Journal of Cancer</i>. 2011;47:230-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/20943374/pubmed\" target=\"_blank\" id=\"20943374\">20943374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2012;30(13):1553-1561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grothey A, Nikcevich DA, Sloan JA, et al, &ldquo;Intravenous Calcium and Magnesium for Oxaliplatin-Induced Sensory Neurotoxicity in Adjuvant Colon Cancer: NCCTG N04C7,&rdquo; <i>J Clin Oncol</i>, 2011, 29(4):421-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/21189381/pubmed\" target=\"_blank\" id=\"21189381\">21189381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hartmann C, Weinel P, Schmid H, et al. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. <i>J Pediatr Hematol Oncol</i>. 2011;33(5):344-349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/21572345/pubmed\" target=\"_blank\" id=\"21572345\">21572345</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hurst S, McMillan M. Innovative solutions in critical care units: extravasation guidelines. <i>Dimens Crit Care Nurs</i>. 2004;23(3):125-128.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/15192356/pubmed\" target=\"_blank\" id=\"15192356\">15192356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kim BH, Bradley T, Tai J, et al. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. <i>Oncology</i>. 2009;76(4):231-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/19246947/pubmed\" target=\"_blank\" id=\"19246947\">19246947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam CG, Furman WL, Wang C, et al. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. <i>J Pediatr Hematol Oncol</i>. 2015;37(1):e13-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/24942022/pubmed\" target=\"_blank\" id=\"24942022\">24942022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). <i>J Clin Oncol</i>. 2013 Dec 2. [Epub ahead of print].</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macy ME, Duncan T, Whitlock J, et.al. A multi-center phase 1b study of oxaliplatin (NSC #266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. <i>Pediatric Blood Cancer</i>. 2013;60:230-236.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/23024067/pubmed\" target=\"_blank\" id=\"23024067\">23024067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic soldi tumors. <i>Pediatric Blood Cancer</i>. 2013;60:1103-1107.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/23335436/pubmed\" target=\"_blank\" id=\"23335436\">23335436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGregor LM, Spunt SL, Santana VM, et.al. Phase I study of an oxaliplatin-etoposide regimen in pediatric patients with recurrent solid tumors. <i>Cancer</i>. 2009;115(3):655-664.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/19117350/pubmed\" target=\"_blank\" id=\"19117350\">19117350</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. <i>Oncology</i>. 2009;76(1):36-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/19033714/pubmed\" target=\"_blank\" id=\"19033714\">19033714</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Herrstedt J, Aapro M, et al; ESMO/MASCC Guidelines Working Group. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. <i>Ann Oncol</i>. 2010;21(suppl 5):v232-v243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/20555089/pubmed\" target=\"_blank\" id=\"20555089\">20555089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Synold TW, Takimoto CH, Doroshow JH, et al, &quot;Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients With Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study,&quot; <i>Clin Cancer Res</i>, 2007, 13(12):3660-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/17575231/pubmed\" target=\"_blank\" id=\"17575231\">17575231</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takimoto CH, Graham MA, Lockwood G, et al, &quot;Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients With Impaired Renal Function,&quot; <i>Clin Cancer Res</i>, 2007, 13(16):4832-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/17699862/pubmed\" target=\"_blank\" id=\"17699862\">17699862</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Takimoto CH, Remick SC, Sharma S, et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. <i>J Clin Oncol</i>. 2003;21(14):2664-2672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/12860942/pubmed\" target=\"_blank\" id=\"12860942\">12860942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and doxorubicin for relapsed or refractory high-risk neuroblastoma. <i>Pediatr Hematol Oncol</i>. 2015;32(1):26-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/oxaliplatin-pediatric-drug-information/abstract-text/25551355/pubmed\" target=\"_blank\" id=\"25551355\">25551355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13031 Version 174.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709183\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F204261\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F6821523\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1028793\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1028825\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F204242\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F204229\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1028831\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132766\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F204256\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1028794\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F204295\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F204291\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F204247\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F204232\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299798\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F204236\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F204238\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F204249\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1028833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F204231\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F204246\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323568\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539908\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13031|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=oxaliplatin-drug-information\" class=\"drug drug_general\">Oxaliplatin: Drug information</a></li><li><a href=\"topic.htm?path=oxaliplatin-patient-drug-information\" class=\"drug drug_patient\">Oxaliplatin: Patient drug information</a></li></ul></div></div>","javascript":null}